PCG Digital: Soligenix Anticipated to Achieve Multiple Milestones in 2021 New York, New York--(Newsfile Corp. - March 16, 2021) - PCG Digital -- The future is looking bright at Soligenix, Inc. In a corporate update released on February 24 th, Dr. Christopher Schaber, Chairman, President and CEO, updated investors on the status of ongoing research projects. The report suggests that multiple milestones will be achieved this year and next. One of the key corporate highlights is the completion of a Phase 3 FLASH ("Fluorescent Light Activated Synthetic Hypericin") study with SGX301 (synthetic hypericin), a treatment for cutaneous T-cell lymphoma (CTCL). Pending FDA clearance, the treatment will be marketed as HyBryte.